SLC10A2
Ileal sodium/bile acid cotransporter
As of the edition of 20 October 2026, SLC10A2 (ileal sodium/bile acid cotransporter, UniProt Q12908) has 5 drugs tested at it and 7 companies on the list, 0 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q12908
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Disease areas
- Digestive system; Inherited and neonatal; Heart and blood vessels; Skin and connective tissue; Nutrition and metabolism; Hormones; Lungs and airways
- Registered trials of its drugs
- 66
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 1 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Maralixibat | Marketed | Phase 4 | Ends 2031 |
| Linerixibat | Marketed | Phase 3 | Ends 2033 |
| Elobixibat | Marketed | Phase 4 | none listed |
| Odevixibat | Marketed | Phase 3 | Ends 2039 |
| Volixibat | Active | Phase 2 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 4 |
| Undetermined | 3 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| Mirum Pharmaceuticals | Route B |
| Ipsen | Route B |
| Takeda | Route B |
The other 4 companies at SLC10A2
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at SLC10A2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.